Safety and Effectiveness of the Genous Endothelial Progenitor Cell-Capture Stent: Follow-Up to 5 Years

AIMS: To evaluate the long-term clinical outcomes following percutaneous coronary intervention (PCI) with the Genous stent in an unselected population. METHODS: All patients admitted to a single center who underwent PCI using the GS exclusively, between May 2006 and May 2012, were enrolled, and a clinical follow-up of up to 60 months was carried out. The primary endpoint of major adverse cardiac event (MACE) rate was defined as the composite of cardiac death, acute myocardial infarction (AMI), and target lesion revascularization (TLR). RESULTS: Of the 450 patients included (75.1% male; 65.5 ± 11.7 years), 28.4% were diabetic and acute coronary syndrome was the reason for PCI in 76.4%. Angioplasty was performed in 524 lesions using 597 Genous stents, with angiographic success in 97.1%. At a median of 36 months of follow-up (range, 1-75 months), MACE, AMI, TLR, stent restenosis (SR), and stent thrombosis (ST) rates were 15.6%, 8.4%, 4.4%, 3.8%, and 2.2%, respectively. Between 12 and 24 months, the TLR, SR, and ST rates practically stabilized, up to 60 months. Bifurcation lesions were independently associated with MACE, TLR, and SR. CONCLUSION: This is the first study reporting clinical results with the Genous stent up to 60 months. The Genous stent was safe and effective in the long-term, in an unselected population.

Solução Industrial para Controlo de OEE

É cada vez mais forte e natural o desenvolvimento de aplicações móveis. Hoje em dia qualquer pessoa seja de forma amadora ou profissional tenta tirar o máximo partido do seu dispositivo móvel, através de aplicações desenvolvidas para as mais diversas áreas. Um dos sistemas operativos que mais programadores apostam é no Android devido à sua versatilidade e ás suas capacidades enquanto sistema operativo dentro de um smartphone. Para além dessas mais-valias, desenvolver uma aplicação para Android não tem qualquer custo, apenas terá, caso seja uma aplicação para adicionar a Google Play Store, caso contrário pode desenvolver-se qualquer tipo de aplicação sem custos, o que não acontece com outros sistemas operativos. Tendo em conta os custos, é normal as pequenas e médias empresas tentarem investir neste tipo de desenvolvimento, pois evitam gastos em licenciamentos para produzir os seus produtos. Seguindo este contexto, esta dissertação insere-se nesse perfil, isto é, tentar encontrar uma solução com baixos custos e que produza os resultados pretendidos. Através das mais diversas API’s é possível adaptar o sistema operativo Android a qualquer área apenas basta enquadrar da melhor maneira ideias e dar asas à imaginação. Desta forma, esta dissertação irá centrar-se na área industrial, na qual o Android pode e deve ser bastante útil, se for usado com rigor. Irá ser abordado o desenvolvimento de aplicações móveis e serão analisadas as tecnologias envolventes no projeto assim como algumas das principais soluções já implementadas e desenvolvidas por empresas no setor e para o sector industrial. O projeto aborda também de que forma é possível aliar o sistema operativo Android á área industrial de forma a permitir um melhor desempenho por parte de todos em prol da empresa á qual está associado. A necessidade de criação desta aplicação, surgiu numa perspectiva de melhoria contínua, com o objectivo de abandonar o procedimento instituído, que era realizado manualmente, passando a fazê-lo de uma forma automática e mais interativa. O processo será realizado pelos colaboradores e terá sempre o seu contributo, mas de uma forma mais rigorosa, simples e eficiente, aumentando a qualidade do serviço.

A política pública de promoção de parques industriais e o seu contributo para o desenvolvimento e o ordenamento do território. Parque industrial de Beja

Relatório de Estágio apresentado para cumprimento dos requisitos necessários à obtenção do grau de Mestre em Gestão do Território, especialização em Planeamento e Ordenamento do Território

Prestação de Serviços de manutenção industrial – uma abordagem económica

Dissertação para obtenção do Grau de Mestre em Engenharia e Gestão Industrial

Atorvastatin versus Bezafibrate in Mixed Hyperlipidaemia : Randomised Clinical Trial of Efficacy and Safety (the ATOMIX Study)

OBJECTIVE: Combined hyperlipidaemia is a common and highly atherogenic lipid phenotype with multiple lipoprotein abnormalities that are difficult to normalise with single-drug therapy. The ATOMIX multicentre, controlled clinical trial compared the efficacy and safety of atorvastatin and bezafibrate in patients with diet-resistant combined hyperlipidaemia. PATIENTS AND STUDY DESIGN: Following a 6-week placebo run-in period, 138 patients received atorvastatin 10mg or bezafibrate 400mg once daily in a randomised, double-blind, placebo-controlled trial. To meet predefined low-density lipoprotein-cholesterol (LDL-C) target levels, atorvastatin dosages were increased to 20mg or 40mg once daily after 8 and 16 weeks, respectively. RESULTS: After 52 weeks, atorvastatin achieved greater reductions in LDL-C than bezafibrate (percentage decrease 35 vs 5; p < 0.0001), while bezafibrate achieved greater reductions in triglyceride than atorvastatin (percentage decrease 33 vs 21; p < 0.05) and greater increases in high-density lipoprotein-cholesterol (HDL-C) [percentage increase 28 vs 17; p < 0.01 ]. Target LDL-C levels (according to global risk) were attained in 62% of atorvastatin recipients and 6% of bezafibrate recipients, and triglyceride levels <200 mg/dL were achieved in 52% and 60% of patients, respectively. In patients with normal baseline HDL-C, bezafibrate was superior to atorvastatin for raising HDL-C, while in those with baseline HDL-C <35 mg/dL, the two drugs raised HDL-C to a similar extent after adjustment for baseline values. Both drugs were well tolerated. CONCLUSION: The results show that atorvastatin has an overall better efficacy than bezafibrate in concomitantly reaching LDL-C and triglyceride target levels in combined hyperlipidaemia, thus supporting its use as monotherapy in patients with this lipid phenotype.

Laboratório remoto de automação industrial (Lab-RAI)

Dissertação para obtenção do Grau de Mestre em Engenharia Electrotécnica e Computadores

Long-Term Lamivudine Treatment of Children with Chronic Hepatitis B: Durability of Therapeutic Responses and Safety

Lamivudine has been demonstrated safe and efficacious in the short term in a large cohort of children with chronic hepatitis B (CHB), but optimal duration of treatment has not been elucidated and limited data on the safety of long-term lamivudine administration have been reported. In addition, the durability of favourable therapeutic outcomes after lamivudine therapy in children has not been well characterized. The aim of this study was to examine the safety of lamivudine and the durability of clinical responses in a group of children who received up to 3 years of treatment for CHB. One hundred and fifty-one children from centres in nine countries who had previously received lamivudine in a large prospective trial were enrolled. During the first year, children had been randomized to either lamivudine or placebo treatment. Subsequently, in a separate extension study, those who remained hepatitis B e antigen (HBeAg) positive were given lamivudine for up to 2 years and those who were HBeAg negative were observed for additional 2 years. Results of these studies have been previously reported. In this study, these children were followed for 2 additional years. Data gathered from medical record review included weight, height, signs and symptoms of hepatitis, alanine aminotransferase (ALT) levels, serologic markers, hepatitis B virus (HBV) DNA levels and serious adverse events (SAEs). Other pharmacological treatments for CHB were allowed according to the practices of individual investigators and were documented. Subjects were divided into two groups for analysis, those who had achieved virological response (VR), defined as HBeAg negative and undetectable HBV DNA by the bDNA assay by the end of the extension study at 3 years, and those who had not. In those who had achieved VR by the end of the extension study, long-term durability of HBeAg seroconversion was 82% and >90% in those who had received lamivudine for 52 weeks and at least 2 years respectively. This compares to 75% for those who had achieved seroconversion after placebo. In those who had not achieved VR by the end of the extension study, an additional 11% did so by the end of the study; they had all received lamivudine in the previous trial, and none had received further treatment during the study. Eight children lost hepatitis B surface antigen during the study and all had received lamivudine at some point during the previous trials. Evaluation of safety data revealed no SAEs related to lamivudine. There was no effect of treatment on weight or height z scores. Clinically benign ALT flares (>10 times normal) were seen in 2% of children. Favourable outcomes from lamivudine treatment of CHB in children are maintained for at least several years after completion of treatment. Up to 3 years of lamivudine treatment is safe in children.

Optimização de um processo industrial: recristalização de um isómero

Dissertação para obtenção do Grau de Mestre em Engenharia Química e Bioquímica

Development of a fuzzy qualitative risk assessment model applied to construction industry

Dissertação para obtenção do Grau de Doutor em Engenharia Industrial

Development and Characterization of bioactive, edible whey protein films and coatings to improve quality and safety of Food products

Dissertação para a obtenção de grau de doutor em Ciências da Engenharia e Tecnologia

Análise e avaliação de riscos ocupacionais em actividades de montagem eléctrica

Dissertação para obtenção do Grau de Mestre em Engenharia e Gestão Industrial

Optimização da produção industrial de produtos cosméticos e detergentes

Dissertação apresentada na Faculdade de Ciências e Tecnologia da Universidade Nova de Lisboa para obtenção do grau de Mestre em Engenharia Química e Bioquímica

Investigation of the regulation mechanisms for bioplastics production from industrial residues

Dissertação para obtenção do Grau de Mestre em Biotecnologia

Safety evaluation of SPF66 malaria vaccine in Brazil

The frequency and description of side effects secondaiy to the subcutaneous application of SPf66 malaria vaccine and placebo are reported for each dose of application in the participants of the vaccine efficacy trial in Brazil. Side effects evaluated two hours after each application were detected in 8.0%, 30.2% and 8.8%, for the Is', and 3"' dose, respectively, in the SPf66group, and in 7.0%, 8.5% and 2.9% in the placebo group. Local reactions such as mild inflammation, nodule and pain or erythema frequently accompanied by pruritus were the most common reactions detected in both groups (3-8%, 29.1% and 8.5% in the SPf66 group and 4.0%, 7.6% and 2.5% in the placebo group). Among vaccinees, local side effects after the 2nd dose were more frequent in females. Systemic side effects were expressed mainly through general symptoms referred by the participants and were most frequent after the 1st dose in both groups (4.3% in the SPf66 group and 3-0% in the placebo group). Muscle aches and fever were refewred by few participants. No severe adverse reactions were detected for either dose of application or group.

Avaliação integrada do risco ocupacional e da segurança alimentar numa unidade hospitalar

Dissertação para obtenção do Grau de Mestre em Engenharia e Gestão Industrial